Related Content
Search Google Scholar for:
|
|
Science 22 September 2006: Vol. 313. no. 5794, pp. 1785 - 1787 DOI: 10.1126/science.1127592
|
|
Reports
Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors
Yuval Shaked,1*
Alessia Ciarrocchi,2*
Marcela Franco,1
Christina R. Lee,1
Shan Man,1
Alison M. Cheung,3
Daniel J. Hicklin,4
David Chaplin,5
F. Stuart Foster,3
Robert Benezra,2
Robert S. Kerbel1
The contribution of bone marrowderived circulating endothelial progenitor cells (CEPs) to tumor angiogenesis has been controversial, primarily because of their low numbers in blood vessels of untreated tumors. We show that treatment of tumor-bearing mice with vascular disrupting agents (VDAs) leads to an acute mobilization of CEPs, which home to the viable tumor rim that characteristically remains after such therapy. Disruption of this CEP spike by antiangiogenic drugs or by genetic manipulation resulted in marked reductions in tumor rim size and blood flow as well as enhanced VDA antitumor activity. These findings also provide a mechanistic rationale for the enhanced efficacy of VDAs when combined with antiangiogenic drugs.
1 Department of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada.
2 Program of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
3 Department of Imaging Research, Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada.
4 ImClone Systems, 180 Varick Street, 7th Floor, New York, NY 10014, USA.
5 OXiGENE Inc., 230 Third Avenue, Waltham, MA 02451, USA.
* These authors contributed equally to this work.
To whom correspondence should be addressed. E-mail: robert.kerbel{at}sri.utoronto.ca
Read the Full Text
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- Tumor Angiogenesis.
- R. S. Kerbel (2008)
N. Engl. J. Med.
358, 2039-2049
| Full Text »
| PDF »
- Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth.
- S. Purhonen, J. Palm, D. Rossi, N. Kaskenpaa, I. Rajantie, S. Yla-Herttuala, K. Alitalo, I. L. Weissman, and P. Salven (2008)
PNAS
105, 6620-6625
| Abstract »
| Full Text »
| PDF »
- Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform-Producing Tumors.
- G. M. Tozer, S. Akerman, N. A. Cross, P. R. Barber, M. A. Bjorndahl, O. Greco, S. Harris, S. A. Hill, D. J. Honess, C. R. Ireson, et al. (2008)
Cancer Res.
68, 2301-2311
| Abstract »
| Full Text »
| PDF »
- Equilibrium between Host and Cancer Caused by Effector T Cells Killing Tumor Stroma.
- B. Zhang, Y. Zhang, N. A. Bowerman, A. Schietinger, Y.-X. Fu, D. M. Kranz, D. A. Rowley, and H. Schreiber (2008)
Cancer Res.
68, 1563-1571
| Abstract »
| Full Text »
| PDF »
- Tissue Inhibitor of Metalloproteinase-3 via Oncolytic Herpesvirus Inhibits Tumor Growth and Vascular Progenitors.
- Y. Y. Mahller, S. S. Vaikunth, M. C. Ripberger, W. H. Baird, Y. Saeki, J. A. Cancelas, T. M. Crombleholme, and T. P. Cripe (2008)
Cancer Res.
68, 1170-1179
| Abstract »
| Full Text »
| PDF »
- Induction of Cancer Metastasis by Cyclophosphamide Pretreatment of Host Mice: An Opposite Effect of Chemotherapy.
- K. Yamauchi, M. Yang, K. Hayashi, P. Jiang, N. Yamamoto, H. Tsuchiya, K. Tomita, A. R. Moossa, M. Bouvet, and R. M. Hoffman (2008)
Cancer Res.
68, 516-520
| Abstract »
| Full Text »
| PDF »
- ID genes mediate tumor reinitiation during breast cancer lung metastasis.
- G. P. Gupta, J. Perk, S. Acharyya, P. de Candia, V. Mittal, K. Todorova-Manova, W. L. Gerald, E. Brogi, R. Benezra, and J. Massague (2007)
PNAS
104, 19506-19511
| Abstract »
| Full Text »
| PDF »
- Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation, and Vasculogenesis Following Anti Vascular Endothelial Growth Factor Receptor-2 Therapy.
- Z. Zhou, M. F. Bolontrade, K. Reddy, X. Duan, H. Guan, L. Yu, D. J. Hicklin, and E. S. Kleinerman (2007)
Clin. Cancer Res.
13, 4867-4873
| Abstract »
| Full Text »
| PDF »
- Vascular disrupting therapy-induced mobilization of circulating endothelial progenitor cells.
- F Farace, C Massard, E Borghi, J-M Bidart, and J-C Soria (2007)
Ann. Onc.
18, 1421-1422
| Full Text »
| PDF »
- Antiangiogenic Strategies on Defense: On the Possibility of Blocking Rebounds by the Tumor Vasculature after Chemotherapy.
- Y. Shaked and R. S. Kerbel (2007)
Cancer Res.
67, 7055-7058
| Abstract »
| Full Text »
| PDF »
- Combination Chemotherapy Including Combretastatin A4 Phosphate and Paclitaxel Is Effective against Anaplastic Thyroid Cancer in a Nude Mouse Xenograft Model.
- S.-C. J. Yeung, M. She, H. Yang, J. Pan, L. Sun, and D. Chaplin (2007)
J. Clin. Endocrinol. Metab.
92, 2902-2909
| Abstract »
| Full Text »
| PDF »
- Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization.
- D. J. Nolan, A. Ciarrocchi, A. S. Mellick, J. S. Jaggi, K. Bambino, S. Gupta, E. Heikamp, M. R. McDevitt, D. A. Scheinberg, R. Benezra, et al. (2007)
Genes & Dev.
21, 1546-1558
| Abstract »
| Full Text »
| PDF »
- Tumor Angiogenesis Promoted by Ex vivo Differentiated Endothelial Progenitor Cells Is Effectively Inhibited by an Angiogenesis Inhibitor, TK1-2.
- H.-K. Oh, J.-M. Ha, E. O, B. H. Lee, S. K. Lee, B.-S. Shim, Y.-K. Hong, and Y. A. Joe (2007)
Cancer Res.
67, 4851-4859
| Abstract »
| Full Text »
| PDF »
- Biomarkers in Gastrointestinal Stromal Tumor: Should We Equate Blood-Based Pharmacodynamics with Tumor Biology and Clinical Outcomes?.
- J. C. McAuliffe and J. C. Trent (2007)
Clin. Cancer Res.
13, 2535-2536
| Full Text »
| PDF »
- Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients.
- C. Igreja, M. Courinha, A. S. Cachaco, T. Pereira, J. Cabecadas, M. G. da Silva, and S. Dias (2007)
Haematologica
92, 469-477
| Abstract »
| Full Text »
| PDF »
- Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy.
- S. Senan and E. F. Smit (2007)
Oncologist
12, 465-477
| Abstract »
| Full Text »
| PDF »
- Biomarkers for Monitoring Antiangiogenic Therapy.
- R. S. Bhatt, P. Seth, and V. P. Sukhatme (2007)
Clin. Cancer Res.
13, 777s-780s
| Abstract »
| Full Text »
| PDF »
- Reassessment of Id1 Protein Expression in Human Mammary, Prostate, and Bladder Cancers Using a Monospecific Rabbit Monoclonal Anti-Id1 Antibody..
- J. Perk, I. Gil-Bazo, Y. Chin, P. de Candia, J. J.S. Chen, Y. Zhao, S. Chao, W. Cheong, Y. Ke, H. Al-Ahmadie, et al. (2006)
Cancer Res.
66, 10870-10877
| Abstract »
| Full Text »
| PDF »
|
|